Homburger advised UBS Group AG on its issuance of AUD 1.25 bn Tier 1 Capital Notes with an equity conversion feature
On September 29, 2025, UBS Group AG successfully completed its offering of AUD 1.25 bn in aggregate principal amount of 6.375 per cent. Tier 1 Capital Notes.
Homburger advises Landis+Gyr on the divestment of its EMEA business to AURELIUS
On September 29, 2025, Landis+Gyr Group AG, a leading global provider of integrated energy management solutions, announced that it has entered into a share purchase agreement to divest its operations in the Europe, Middle East and Africa (EMEA) region to AURELIUS, a global private equity investor, for an enterprise value of USD 215 m.
Homburger advised 21Shares on the listing of three new series of crypto-linked exchange traded products as well as cross-listing of three existing series of crypto-linked exchange traded products on SIX Swiss Exchange
On August 29, 2025, September 17, 2025 and September 30, 2025, respectively, 21Shares AG, a leading global issuer of crypto exchange traded products (ETPs), successfully issued and listed three new series of crypto-linked ETPs on the SIX Swiss Exchange. The first series, 21Shares Hyperliquid ETP (HYPE), has Hyperliquid (HYPE) as underlying, the native token of …
Homburger advised Luzerner Kantonalbank AG on the issuance of its CHF 200 m 1.400% Tier 2 Bonds
On September 17, 2025, Luzerner Kantonalbank AG issued CHF 200 m 1.400% Tier 2 Bonds.
Homburger advised Santhera in connection with its CHF 20 m Royalty Monetization and Convertible Bond Financing
On September 23, 2025, Santhera Pharmaceuticals Holding AG (SIX: SANN) announced that it had secured an USD 13 m royalty monetization financing with R-Bridge, an affiliate of CBC Group, Asia’s largest healthcare-focused investment firm. Santhera is monetizing 25% of net royalties on its product AGAMREE®.
Homburger advised UBS Group AG on its issuance of USD 5 bn Fixed Rate/Floating Rate Callable Senior Notes and Floating Rate Callable Senior Notes under its Senior Debt Programme
On September 23, 2025, UBS Group AG successfully completed its issuance of (i) USD 1.25 bn Fixed Rate/Floating Rate Callable Senior Notes due December 2029,
Homburger advised Madrigal in connection with its new USD 500 m financing
On July 17, 2025, Madrigal Pharmaceuticals, Inc., a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need, secured a USD 500 m senior secured credit facility from Blue Owl Capital to advance its pharmaceutical pipeline.
Homburger advised Givaudan SA on the issuance of EUR 500 m Guaranteed Bonds due 2029 guaranteed by Givaudan SA
On September 9, 2025, Givaudan Finance Europe B.V. successfully completed its issuance of EUR 500 m 2.875 per cent. Guaranteed Bonds due 2029 guaranteed by Givaudan SA. The Bonds are governed by English law and listed on Euronext Dublin. The Homburger team was led by Daniel Haeberli and included Daniel Hulmann (both Capital Markets) and …
Homburger advised UBS Switzerland AG on the issuance of an aggregate amount of EUR 1 bn Fixed Rate Covered Bonds
On September 9, 2025, UBS Switzerland AG successfully completed its issuance of EUR 1 bn 2.783 per cent.
Homburger advised UBS Switzerland AG on the issuance of an aggregate amount of CHF 510 m Fixed Rate Covered Bonds
On August 13, 2025, UBS Switzerland AG successfully completed its issuance of CHF 235 m 0.560 per cent. Fixed Rate Covered Bonds due August 13, 2030, and CHF 275 m 0.935 per cent. Fixed Rate Covered Bonds due August 13, 2035, under its Covered Bond Programme. The Covered Bonds are governed by Swiss law and …